Alkem Laboratories will host a conference call on Friday, August 14, 2026, at 4:30 PM IST to discuss its Q1FY27 financial results. The event provides investors and analysts an opportunity to review the company’s performance for the quarter ending September 30, 2026, following the release of the official financial statements. This disclosure aligns with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency in corporate communications.

The conference call will be conducted by Motilal Oswal Securities Ltd., which will facilitate the interaction between the company’s leadership and the investment community. Alkem Laboratories’ management team will be represented by Sandeep Singh, Managing Director, and Nitin Agrawal, Chief Financial Officer. These executives are expected to address operational highlights, financial metrics, and strategic initiatives relevant to the quarter.

Conference Call Details

Participants can join the call via dial-in numbers provided for domestic and international attendees. The session is scheduled to last from 4:30 PM to 5:30 PM IST. Investors are advised to dial in 10 minutes prior to the start time to ensure seamless entry.

Access and Registration

For those preferring digital access, an Express Join option is available via the Diamond Pass registration link provided in the official intimation. This method allows participants to bypass initial waiting lines and join the conference directly. The registration process requires a confirmation number and security string, ensuring secure access for verified attendees.

Key Participants

The primary speakers for the session include:

• Sandeep Singh, Managing Director
• Nitin Agrawal, Chief Financial Officer

Tushar Manudhane, Institutional Research Analyst – Healthcare at Motilal Oswal Securities Ltd., will oversee the research aspect of the call. For further inquiries regarding investor relations or media coverage, Purvi Shah and Isha Trivedi from Alkem Laboratories’ Investor Relations department are available for contact.

What the Numbers Show

While specific financial figures are not detailed in this announcement, the scheduling of the call indicates that Alkem Laboratories has completed its audit and compliance processes for Q1FY27. The involvement of Motilal Oswal Securities Ltd. suggests a structured approach to disseminating information to institutional and retail investors alike. Market participants should monitor the subsequent release of the full earnings transcript for detailed insights into revenue trends, profit margins, and future guidance.

Alkem Laboratories Limited has accepted the resignation of Dr. Jitendra Singh Huda from the position of Senior Vice President, effective July 23, 2026. The pharmaceutical company disclosed that Dr. Huda tendered his resignation to pursue professional growth opportunities. Consequently, he will cease to hold his senior management position within the organization starting from the stated date, marking a leadership transition in its senior management team.

The resignation process was initiated via email on July 14, 2026, and formally accepted by Dr. Rajorshi Ganguli, President and Global HR Head, on July 15, 2026. In his resignation communication, Dr. Huda confirmed his availability until July 23, 2026, to complete pending responsibilities and ensure a smooth handover of duties. The company acknowledged the valuable contributions made by Dr. Huda during his tenure as Senior Management Personnel.

Regulatory Disclosure

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted by Divya Mewani, Vice President – Legal & Deputy Company Secretary. The company also referenced SEBI Master Circular bearing No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, in its submission.

The specific details regarding the change in senior management were provided in Annexure I to the regulatory filing. A copy of the resignation letter tendered by Dr. Huda was enclosed as Annexure II. The information is also available on the company’s website.

Key Details of Resignation